
Alzheimer's drug Aduhelm, which is marketed in a collaboration between Biogen and Eisai, is facing many problems -- the latest of which is found in Japan.
Friday's rejection of Aduhelm in the EU has been followed by a similar decision in Japan, where the national health authority is requiring more data pertaining to the drug's efficacy, the companies report in a shared statement.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app